A dose proportionality study of eprosartan in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1998, Pages 34-39

  Chapelsky, Martha C ^a   Martin, David E ^b   Tenero, David M ^a   Ilson, Bernard E ^b   Boike, Steven C ^b   Etheredge, Rickey ^a   Jorkasky, Diane K ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PH; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

EID: 0031935340     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04374.x     Document Type: Article

References (9)

1. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist. SK&F 108566. J Pharmacol Exp Ther 1992;260:175-181.
2. Ilson B, Boike S, Audet P, Freed M, Everitt D, Brown L, et al: Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin (AII) antagonist (abstract). Clin Pharmacol Ther 1994;55:206.
3. Cox PJ, Bush BD, Gorycki PD, Kuo GY, Kenworthy D, Law DW, et al: The metabolic fate of eprosartan in healthy volunteers. Exp Toxicol Pathol 1996;48(Suppl II):75-82.
4. Lundberg DE, Person CR, Knox S, Cyronak M: Determination of SK&F 108566 in human plasma by solid-phase extraction cleanup and reversed-phase high-performance liquid chromatography. J Chromatogr (in press).
5. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6:539-547.
6. Lovering EG, McGilveray IJ, McMillan I, Tostowaryk EG: Comparative bioavailabilities form truncated blood level curves. J Pharm Sci 1975;64:1521-1524.
7. SAS Institute: SAS/STAT User's Guide, Volumes 1-2, Version 6. Cary, NC: SAS Institute, 1990.
8. Steinijans VW, Deletti E: Statistical analysis of bioavailability studies: parametric and non-parametric confidence intervals. Eur J Clin Pharmacol 1983;24:127-136.
9. Boddy AW, Snikeris FC, Kringle RO, Wei GC, Oppermann JA, Midha KK: An approach for widening the bioequivalence acceptance limits in case of highly variable drugs. Pharm Res 1995;12:1865-1868.